JP2014521647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521647A5 JP2014521647A5 JP2014522900A JP2014522900A JP2014521647A5 JP 2014521647 A5 JP2014521647 A5 JP 2014521647A5 JP 2014522900 A JP2014522900 A JP 2014522900A JP 2014522900 A JP2014522900 A JP 2014522900A JP 2014521647 A5 JP2014521647 A5 JP 2014521647A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazolidin
- ylidene
- amine
- compound
- quinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- YQUZWAPDAWZCIB-UHFFFAOYSA-N N-(4,5-dihydro-1H-imidazol-2-yl)quinolin-4-amine Chemical compound N1CCNC1=NC1=CC=NC2=CC=CC=C12 YQUZWAPDAWZCIB-UHFFFAOYSA-N 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 210000003491 Skin Anatomy 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 5
- MEXZNUBCENYKBM-UHFFFAOYSA-N 4-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinolin-3-amine Chemical compound C1=NC2=CC=CC=C2C(Br)=C1N=C1NCCN1 MEXZNUBCENYKBM-UHFFFAOYSA-N 0.000 claims 4
- CAUKUOLHQRAMJN-UHFFFAOYSA-N 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)quinolin-3-amine Chemical compound C1=NC2=CC=CC=C2C(Cl)=C1N=C1NCCN1 CAUKUOLHQRAMJN-UHFFFAOYSA-N 0.000 claims 4
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 4
- QZOLONZMWNEURB-UHFFFAOYSA-N N-(4,5-dihydro-1H-imidazol-2-yl)-4-methylquinolin-3-amine Chemical compound C1=NC2=CC=CC=C2C(C)=C1N=C1NCCN1 QZOLONZMWNEURB-UHFFFAOYSA-N 0.000 claims 4
- QLBLUIVFHAMMAR-UHFFFAOYSA-N N-(4,5-dihydro-1H-imidazol-2-yl)-8-methylpyrido[2,3-b]pyrazin-7-amine Chemical compound C1=NC2=NC=CN=C2C(C)=C1N=C1NCCN1 QLBLUIVFHAMMAR-UHFFFAOYSA-N 0.000 claims 4
- GZYJIQHBCURBQY-UHFFFAOYSA-N N-(4,5-dihydro-1H-imidazol-2-yl)pyrido[2,3-b]pyrazin-7-amine Chemical compound N1CCNC1=NC1=CN=C(N=CC=N2)C2=C1 GZYJIQHBCURBQY-UHFFFAOYSA-N 0.000 claims 4
- LYFHAPSWVAJTFJ-UHFFFAOYSA-N N-(4,5-dihydro-1H-imidazol-2-yl)quinolin-3-amine Chemical compound N1CCN=C1NC1=CN=C(C=CC=C2)C2=C1 LYFHAPSWVAJTFJ-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- XLZYJCBTCAHAAB-UHFFFAOYSA-N 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-1,5-naphthyridin-3-amine Chemical compound C1=NC2=CC=CN=C2C(Cl)=C1N=C1NCCN1 XLZYJCBTCAHAAB-UHFFFAOYSA-N 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- -1 imidazolidin-2-ylidene Chemical group 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 206010037844 Rash Diseases 0.000 claims 1
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000009056 Telangiectasis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 231100001005 telangiectasia Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161511298P | 2011-07-25 | 2011-07-25 | |
| US61/511,298 | 2011-07-25 | ||
| PCT/US2012/047570 WO2013016178A1 (en) | 2011-07-25 | 2012-07-20 | N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521647A JP2014521647A (ja) | 2014-08-28 |
| JP2014521647A5 true JP2014521647A5 (ru) | 2015-09-10 |
| JP6031719B2 JP6031719B2 (ja) | 2016-11-24 |
Family
ID=46582084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014522900A Active JP6031719B2 (ja) | 2011-07-25 | 2012-07-20 | アルファ２アドレナリン作動性受容体のモジュレーターとしてのｎ−（イミダゾリジン−２−イリデン）キノリン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8815861B2 (ru) |
| EP (1) | EP2736902A1 (ru) |
| JP (1) | JP6031719B2 (ru) |
| KR (1) | KR20140062471A (ru) |
| CN (1) | CN103827107A (ru) |
| AU (1) | AU2012287164A1 (ru) |
| BR (1) | BR112014001938A2 (ru) |
| CA (1) | CA2843251A1 (ru) |
| HK (1) | HK1198762A1 (ru) |
| RU (1) | RU2014106364A (ru) |
| WO (1) | WO2013016178A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8941159B2 (en) | 2013-01-30 | 2015-01-27 | Omnivision Technologies, Inc. | Color filter including clear pixel and hard mask |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB889282A (en) | 1957-05-07 | 1962-02-14 | Air Reduction | Preparation of hexafluorodiethyl ether and medicinal compositions containing it |
| BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| EP1285657A3 (en) | 1993-10-13 | 2003-08-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5576437A (en) | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| NZ333370A (en) * | 1993-12-17 | 2001-03-30 | Procter & Gamble | 6-(2-Imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| ATE194771T1 (de) * | 1993-12-17 | 2000-08-15 | Procter & Gamble | 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten |
| EP0775134A4 (en) | 1994-08-04 | 1997-08-13 | Synaptic Pharma Corp | NEW BENZIMIDAZOLE DERIVATIVES |
| US6087361A (en) * | 1995-05-12 | 2000-07-11 | Allergan Sales, Inc. | Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects |
| CA2220517A1 (en) * | 1995-05-12 | 1996-11-14 | Allergan | Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects |
| US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| AU2010303545B2 (en) * | 2009-10-06 | 2016-05-12 | Allergan, Inc. | 2H-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators |
-
2012
- 2012-07-20 US US13/554,546 patent/US8815861B2/en active Active
- 2012-07-20 KR KR1020147004720A patent/KR20140062471A/ko not_active Application Discontinuation
- 2012-07-20 CA CA2843251A patent/CA2843251A1/en not_active Abandoned
- 2012-07-20 WO PCT/US2012/047570 patent/WO2013016178A1/en active Application Filing
- 2012-07-20 JP JP2014522900A patent/JP6031719B2/ja active Active
- 2012-07-20 BR BR112014001938A patent/BR112014001938A2/pt not_active IP Right Cessation
- 2012-07-20 CN CN201280046305.5A patent/CN103827107A/zh active Pending
- 2012-07-20 RU RU2014106364/04A patent/RU2014106364A/ru not_active Application Discontinuation
- 2012-07-20 EP EP12740272.5A patent/EP2736902A1/en not_active Withdrawn
- 2012-07-20 AU AU2012287164A patent/AU2012287164A1/en not_active Abandoned
-
2014
- 2014-07-15 US US14/332,110 patent/US9199989B2/en active Active
- 2014-12-04 HK HK14112237.2A patent/HK1198762A1/xx unknown
-
2015
- 2015-10-28 US US14/925,065 patent/US20160045489A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101893632B1 (ko) | 아레나바이러스 감염의 치료를 위한 항바이러스 약물 | |
| EP2462138B1 (en) | Antiviral compounds and methods of making | |
| ES2651162T3 (es) | Antagonistas fluorados de integrina | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2017533968A5 (ru) | ||
| JP2016505637A5 (ru) | ||
| JP2011042668A5 (ru) | ||
| JP2014502641A5 (ru) | ||
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| JP2014506582A5 (ru) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| JP2015521195A5 (ru) | ||
| EP1613310A1 (en) | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | |
| JP2018538357A (ja) | 化合物 | |
| JP2015083565A5 (ru) | ||
| JP2022116328A (ja) | 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物 | |
| IL269698A (en) | Methods for the prevention or treatment of eye diseases | |
| JP2014521647A5 (ru) | ||
| JP2014521642A5 (ru) | ||
| RU2014106364A (ru) | Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2 | |
| FI3519050T3 (fi) | Koostumuksia silmätautien hoitamiseksi | |
| JP2013521316A5 (ru) | ||
| EA201991008A1 (ru) | Новые производные нафтиридинона и их применение в лечении аритмии | |
| TH167758B (th) | อนุพันธ์อะซาอินโดลอะซิติกแอซิดและการใช้อนุพันธ์ดังกล่าว เป็นสารควบคุมตัวรับพรอสตาแกลนดิน d2 | |
| EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |